AI summary · may contain errors
The CHARGE prognostic index stratifies relapsed/refractory multiple myeloma patients receiving BCMA- or talquetamab T-cell engagers into three PFS risk groups, including a high-risk median PFS of 1.6 months.
Moving in Annals of Neurology, Brain, Nature Reviews Neurology, bioRxiv, JAMA Neurology, medRxiv, The Lancet Neurology and Leukemia.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
The CHARGE prognostic index stratifies relapsed/refractory multiple myeloma patients receiving BCMA- or talquetamab T-cell engagers into three PFS risk groups, including a high-risk median PFS of 1.6 months.
AI summary · may contain errors
Platelet-to-lymphocyte ratio is modestly higher in Neuromyelitis Optica Spectrum Disorders patients than in healthy subjects (pooled MD 23.99 [6.03; 41.96]).
AI summary · may contain errors
In a Japanese multicenter cohort of 601 patients with first-episode optic neuritis, 27.6% developed additional CNS inflammatory events over a median 2 years, with recurrent optic neuritis most common.
AI summary · may contain errors
Propionate levels in plasma and paired stool samples are consistently linked to lower disease activity in pediatric-onset multiple sclerosis, with replication in an external cohort.
AI summary · may contain errors
In treatment-naïve Guillain-Barré syndrome, CSF shows compartmental enrichment of Th1-polarized CD4+ and activated/resident-memory CD8+ T cells plus macrophages, exceeding healthy controls.
AI summary · may contain errors
Adoptive T cell therapies are positioned as “living drugs” that can expand, adapt, and persist in vivo, with rapid preliminary reports and trials in nervous system inflammatory and infectious diseases.
AI summary · may contain errors
SuStaIn applied to multimodal 3 T MRI in 1017 multiple sclerosis patients identifies four reproducible MRI subtypes—lesion-led (44%), cortex-led (23%), tract-led (23%), and deep grey matter/cerebellar-led (10%).
AI summary · may contain errors
Low-dose IL-2 did not expand regulatory T cells in alemtuzumab-treated relapsing-remitting multiple sclerosis patients more than 6 months after therapy, despite prior in vitro and mouse selectivity.
AI summary · may contain errors
The 2024 McDonald diagnostic criteria for multiple sclerosis broaden acceptable evidence, but their safe use outside expert centres is uncertain given variable imaging, labs, and interpretation.
AI summary · may contain errors
ALS-RAP generated KO-validated antibodies for 33 ALS-associated proteins, characterizing 303 antibodies to produce a publicly available toolbox and protein expression resource.
AI summary · may contain errors
HLA-DRB1*04:01 is strongly associated with self-reported cefaclor adverse-reaction labels in 70,724 NMDP donors, with OR = 3.74 (p = 5.10E-28).
AI summary · may contain errors
Cortical demyelination in multiple sclerosis has become a central pathological feature, with subpial and brain–cerebrospinal fluid interface inflammation linked to progression independent of relapse activity.
AI summary · may contain errors
In adults with systemic lupus erythematosus and objective neuropsychological dysfunction, 12-week memantine improved RBANS total scores versus placebo (median change +8 vs +5; P = .032).
AI summary · may contain errors
Continuous ocrelizumab over 10 years in relapsing multiple sclerosis is linked to a 24% lower hazard of 48-week confirmed disability progression versus delayed initiation.
AI summary · may contain errors
Premorbid behavioral regulation is most strongly linked to behavioral impairment in 965 consecutively assessed ALS patients, with higher educational attainment and social exposure associated with lower odds.
AI summary · may contain errors
Tamoxifen-induced microglia/macrophage SIK3 knockout in mice increases CD11c and C1q in the 400–800 µm peri-infarct zone, boosting myelin debris clearance by 19.0%.
AI summary · may contain errors
A reproducible pre-relapse immune signature in monocytes and B cells emerges up to 3 months before relapse in relapsing-remitting MS, linked to EBV lytic reactivation programs.
AI summary · may contain errors
Complement-targeted therapeutics are poised to expand beyond antibody-driven disorders, with a growing pipeline aimed at inhibiting proximal or distal complement components in autoimmune and possibly degenerative neurological diseases.
AI summary · may contain errors
The gut wall’s intestinal barrier, enteric nervous system, and mucosal immunity are underexplored contributors to multiple sclerosis and autoimmune neurologic disease pathogenesis and progression.
Journals this month
Topics moving, week to 17 Nov 2026
By field